The arrival of anti-vascular endothelial growth factor (anti-VEGF) therapies, such as aflibercept and ranibizumab, has marked a significant advancement in the therapeutic landscape for AMD, diabetic macular oedema (DMO), and retinal vein occlusion (RVO) [1-3]. The gene discussed is VEGFA; the disease is age-related macular degeneration.